Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06593847 · ClinicalTrials.gov registry record · NA
Multisite Virtual Reality Intervention for Speech Anxiety
A NA study, sponsored by Boston University Charles River Campus.
- Completed
- Registry status
- NA
- Development phase
- 1,542
- Enrollment target
NCT06593847: Completed NA study, sponsored by Boston University Charles River Campus.
NCT06593847 is a NA study that has completed, run by Boston University Charles River Campus. The registered enrollment target is 1,542 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (10% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06593847, a NA study, has completed, sponsored by Boston University Charles River Campus.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,542 participants
- Enrollment target
Study Summary
Exposure-based cognitive behavior therapy is an efficacious treatment for speech anxiety and has been delivered effectively in a virtual reality (VR) environment. The present multicenter study (conducted through the Exposure Therapy Consortium) is designed to evaluate whether trait versus state positive affectivity is a more effective predictor of exposure therapy outcomes. Further, the investigators will examine whether the predictive significance of trait positive affectivity can be accounted for by examination of baseline levels of self-efficacy, hope, and optimism.
Primary Outcome
Assessed using the Personal Report of Communication Apprehension, Public Speaking Subscale (PRCA-PS). Scores range from 6 to 30, with higher scores associated with higher public speaking anxiety.
Interventions
- BEHAVIORAL Single-session VR exposure intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,542 participants |
| Start Date | 2024-10-08 |
| Est. Completion | 2025-07-23 |
| Phase | NA |
What the finished NCT06593847 record still lists
NCT06593847 is an interventional study that assigns participants to a tested intervention. Its 1,542 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (10% higher).
The record links to 0 conditions, and to 1 intervention - of which Single-session VR exposure intervention is the first listed.
NCT06593847 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06593847 about?
NCT06593847 is a clinical study titled "Multisite Virtual Reality Intervention for Speech Anxiety". Exposure-based cognitive behavior therapy is an efficacious treatment for speech anxiety and has been delivered effectively in a virtual reality (VR) environment. The present multicenter study (conducted through the Exposure Therapy Consortium) is designed to evaluate whether trait versus state posi...
What is the current status of trial NCT06593847?
This trial is currently completed. It is a NA study. The enrollment target is 1,542 participants. The study started on 2024-10-08. Estimated completion is 2025-07-23.
What interventions are being tested in trial NCT06593847?
The interventions under investigation include: Single-session VR exposure intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT06593847?
This trial is sponsored by Boston University Charles River Campus, which has 104 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06593847's enrollment target sits among peer trials
1,542 65th of 2000 higher than 1,936 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03435796 · 1,541 participants · Phase 2
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
- NCT06729775 · 1,546 participants · NA
Disentangling the Role of Culture, Life Stage, and Information Design to Facilitate Equity in Data Report Back
- NCT06842875 · 1,536 participants · NA
Rhode Island - Statewide Postpartum Hypertension Remote Surveillance
- NCT02650622 · 1,550 participants
Genetic and Metabolic Disease in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI